Prudential Financial’s Viking Therapeutics VKTX Stock Holding History

Prudential Financial’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-7,395	Closed	-$295K	–	2535
2025 Q2	$295K	Buy	+7,395	New	+$195K	﹤0.01%	2102
2024 Q4	–	Sell	-48,600	Closed	-$3.08M	–	2730
2024 Q3	$3.08M	Sell	48,600 -18,846	-28%	-$1.11M	﹤0.01%	1228
2024 Q2	$3.58M	Buy	67,446 +59,619	+762%	+$3.91M	0.01%	1075
2024 Q1	$642K	Buy	+7,827	New	+$348K	﹤0.01%	2064
2022 Q2	–	Sell	-101,970	Closed	-$306K	–	2750
2022 Q1	$306K	Buy	101,970 +66,300	+186%	+$238K	﹤0.01%	2391
2021 Q4	$164K	Buy	+35,670	New	+$200K	﹤0.01%	2564

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Prudential Financial's VKTX Position: Q3 2025 in Review

Prudential Financial sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 7,395 shares — an estimated $295K sold.

Prudential Financial first reported a position in VKTX in Q4 2021 and held it in 6 quarters. The position peaked at $3.58M in Q2 2024. 371 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

Prudential Financial reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
Prudential Financial sold 7,395 Viking Therapeutics shares in Q3 2025, an estimated $295K.
Prudential Financial first reported a position in Viking Therapeutics in Q4 2021 and held it in 6 quarters.
Prudential Financial's Viking Therapeutics position peaked at $3.58M in Q2 2024.
371 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Prudential Financial's 13F filing for Q3 2025, filed 13 Nov 2025.